Cabaletta Bio reports positive rese-cel data across autoimmune indications at EULAR 2026

Cabaletta announced encouraging Phase 1/2 clinical data for rese-cel across dermatomyositis, systemic sclerosis, and lupus, with 83% of dermatomyositis patients meeting registrational endpoints and maintaining responses off immunomodulators. The company plans to initiate systemic sclerosis registrational studies in 4Q26 and include juvenile dermatomyositis in a 2H27 myositis BLA submission, potentially supporting faster regulatory pathways.